D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)

NCT00827281 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-05-01

No results posted yet for this study

Summary

This study examines whether isolated doses of D-cycloserine enhance the efficacy of CBT for smoking cessation.

Conditions

  • Smokers

Interventions

DRUG

D-cycloserine

Single dosage prior to sessions 3, 4 \& 5

DRUG

Placebo

Single dosage prior to sessions 3, 4 \& 5

Sponsors & Collaborators

  • Boston University Charles River Campus

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2015-07-15
Completion
2015-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827281 on ClinicalTrials.gov